This paper presents the use of fuzzy logic technique to control the reactive power of load and hence improve the source power factor. A shunt compensator is proposed, which consists of a voltage controlled reactor by ...This paper presents the use of fuzzy logic technique to control the reactive power of load and hence improve the source power factor. A shunt compensator is proposed, which consists of a voltage controlled reactor by full-wave thyristor bridge in parallel with a capacitor. The proposed voltage control technique composed of two independent fuzzy controllers, primary and secondary. The PFC （primary fuzzy controller） is designed based on linearization method to introduce to the network the nearest value of reactive power （VAR） required to correct the power factor. The SFC （secondary fuzzy controller） is designed to achieve accurate compensation for the required VAR to achieve the pre-set power factor value. Simulations for 15 different practical study cases are presented to evaluate the performance of the controller, and the results show how the designed controller is fast and accurate. Harmonics analyses are carried out up to the 13th harmonic to determine the requirement of harmonics filter.展开更多
Because inflammation plays a key role in the pathogenesis of dry eye disease and Sjogren's syndrome, topical anti-inflammatory agents such as corticosteroids and cyclosporine A have been used to treat inflammation...Because inflammation plays a key role in the pathogenesis of dry eye disease and Sjogren's syndrome, topical anti-inflammatory agents such as corticosteroids and cyclosporine A have been used to treat inflammation of the ocular surface and lacrimal gland. Systemic biological agents that target specific immune molecules or cells such as tumor necrosis factor(TNF)-α, interferone-α, interleukin(IL)-1, IL-6, or B cells have been used in an attempt to treat Sjogren's syndrome. However, the efficacy of systemic biological agents, other than B-cell targeting agents, has not yet been confirmed in Sjogren's syndrome. Several studies have recently evaluated the efficacy of topical administration of biological agents targeting cytokines in the treatment of dry eye disease. Topical blockade of IL-1 by using IL-1 receptor antagonist could ameliorate clinical signs and inflammation of experimental dry eye. Using a mouse model of desiccating stress-induced dry eye, we have demonstrated that topical application of a TNF-α blocking agent, infliximab, could improve tear production and ocular surface irregularity, decrease inflammatory cytokines and Th-1 CD4+ cells on the ocular surface, and increase gobletcell density in the conjunctiva. Although controversy still remains, the use of topical biological agents targeting inflammatory cytokines may be a promising therapy for human dry eye disease.展开更多
文摘This paper presents the use of fuzzy logic technique to control the reactive power of load and hence improve the source power factor. A shunt compensator is proposed, which consists of a voltage controlled reactor by full-wave thyristor bridge in parallel with a capacitor. The proposed voltage control technique composed of two independent fuzzy controllers, primary and secondary. The PFC （primary fuzzy controller） is designed based on linearization method to introduce to the network the nearest value of reactive power （VAR） required to correct the power factor. The SFC （secondary fuzzy controller） is designed to achieve accurate compensation for the required VAR to achieve the pre-set power factor value. Simulations for 15 different practical study cases are presented to evaluate the performance of the controller, and the results show how the designed controller is fast and accurate. Harmonics analyses are carried out up to the 13th harmonic to determine the requirement of harmonics filter.
基金Supported by The Chonnam Natinal University Hospital Biomedical Research Institute(CRI 11076-21 and 13906-22)Forest Science and Technology Projects,No.S121313L050100provided by Korea Forest Service
文摘Because inflammation plays a key role in the pathogenesis of dry eye disease and Sjogren's syndrome, topical anti-inflammatory agents such as corticosteroids and cyclosporine A have been used to treat inflammation of the ocular surface and lacrimal gland. Systemic biological agents that target specific immune molecules or cells such as tumor necrosis factor(TNF)-α, interferone-α, interleukin(IL)-1, IL-6, or B cells have been used in an attempt to treat Sjogren's syndrome. However, the efficacy of systemic biological agents, other than B-cell targeting agents, has not yet been confirmed in Sjogren's syndrome. Several studies have recently evaluated the efficacy of topical administration of biological agents targeting cytokines in the treatment of dry eye disease. Topical blockade of IL-1 by using IL-1 receptor antagonist could ameliorate clinical signs and inflammation of experimental dry eye. Using a mouse model of desiccating stress-induced dry eye, we have demonstrated that topical application of a TNF-α blocking agent, infliximab, could improve tear production and ocular surface irregularity, decrease inflammatory cytokines and Th-1 CD4+ cells on the ocular surface, and increase gobletcell density in the conjunctiva. Although controversy still remains, the use of topical biological agents targeting inflammatory cytokines may be a promising therapy for human dry eye disease.
